Precision diagnosis platform company Engene Bio and vision AI specialist company C-Lab announced on the 29th that they signed a strategic business agreement (MOU) for the development of an ‘AI-based customized cancer treatment and prediction platform.’
Through this agreement, the two companies plan to combine their genome analysis and clinical data processing technologies with their multimodal AI model development capabilities to advance precision medicine solutions. The main purpose of the collaboration is to build a cancer treatment prediction platform specialized for the domestic medical environment and develop a system that supports patient-tailored treatment strategies.
In this joint project, EngeneBio will develop a cancer treatment response prediction model based on its NGS (Next Generation Sequencing)-based genome analysis technology and clinical data, and Seelab will design a multimodal AI algorithm that integrates and analyzes genome, image, and clinical data based on its vision-language integrated model (VLM) technology. Seelab will also be responsible for AI model learning and operation optimization by building a GPU-based MLOps platform.
EngeneBio plans to standardize large-scale cancer diagnosis data collected in cooperation with domestic hospitals and research institutes and refine it into learning data for AI model learning. Through this, the company aims to contribute to improving the accuracy of treatment response prediction.
As an official software partner of NVIDIA, Seelab has developed AI solutions that can integrate medical images and genomic information based on its technological prowess in the industrial AI field. In this collaboration, it will lead the construction of a multimodal learning system specialized in medical data and related software infrastructure.
The two companies plan to expand their collaboration to various disease areas, including cancer, and aim to enter the domestic and international precision medicine market in the long term. In particular, this collaboration is noteworthy in that it is an attempt to localize a precision medicine-based system like the US's 'Tempus AI' in a situation where there is a lack of similar platforms in Korea.
EngeneBio CEO Choi Dae-chul said, “This collaboration, which expands from precision diagnosis technology to cancer treatment prediction, will become one axis of implementing AI-based practical medical technology,” adding, “We will strengthen the competitiveness of the precision medicine field by combining medical data and AI technology.”
Se-hyeok Yoon, CEO of Cielab, said, “If existing AI technology was focused on diagnosis, this collaboration is meaningful in that it marks a shift toward predicting treatment effects,” adding, “We will expand the potential use of AI in the medical industry by developing a multimodal AI model that integrates various medical data.”
- See more related articles
You must be logged in to post a comment.